Current Location:School > Home > Doctoral Supervisor

LIU Zhenming

Associate Professor

Zhenming Liu

Associate Professor, Ph.D. supervisor

State Key Laboratory of Natural and Biomimetic Drugs

Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center

38 Xueyuan Road, Haidian District, Beijing 100083, P.R. China

Tel: 86-10-82805514 (Lab); 86-13311134423 (Mobile)

Email: zmliu@bjmu.edu.cn

Research Areas and interesting

Medicinal Chemistry and Molecular Design

Pharmaceutical Informatics

Education & Positions

Peking University Health Sciences Center (PKU-SC), B.S., 2000

Peking University, Ph.D., 2005

Peking University Health Sciences Center (PKU-SC), Assistant Professor 2002-2011

Project officer, China National Center for Biotechnology Development(CNCBD), Ministry of Science and Technology of the People's Republic of China2007-2009

FFCSA, Postdoctoral Fellow, 2009-2011

Peking University Health Sciences Center (PKU-SC), Associate Professor 2011-

Project officer, DevelpmengtCenter for Medical Science and Technology (DCMST), National Health and Family Planning Commission of the People's Republic of China2015-2017

Project officer, National Science and Technology Major Projects for "Major New Drugs Innovation and Development" Special office, National Health and Family Planning Commission of the People's Republic of China 2015-2017

Faculty Accolades

1) Prominent teacher of Peking University (2009)

2) Prominent teacher of Peking University (2007)

3) The CPA-Servier Young Investigator Awards in Medicinal Chemistry by Chinese Pharmaceutical Association (2006)

Research Interests

Our research is focused on developing new drug/ molecular design methods that are relevant to the lead discovery and applying them in the medicinal potential developing of newly synthesized natural products and analogs thereof.

Grants and fundings:

1. The National Natural Science Foundation of China (NSFC, 21772005): Design, synthesis and biological evaluation of novel potent specific inhibitors of Ataxia-Telangiectasia Mutant (ATM) Kinase. 2018.1-2021.12.

2. The National Natural Science Foundation of China (NSFC, 2157020178): Structure-based design, synthesis and discovery of potent specific endothelial lipase (EL) inhibitors. 2016.1-2019.12.

3. The National Natural Science Foundation of China (NSFC,21272017): Design, synthesis and biological evaluation of non-covalent CD38 inhibitors. 2013.1-2016.12.

4. The National High Technology Research and Development Program of China (863 program, 2012AA020308): Techniques for drug target discovery and drug molecular design. 2012.1-2015.12.

5. The National Natural Science Foundation of China (NSFC,20802006): Design, synthesis and biological evaluation of CD38 inhibitors. 2009.1-2011.12.

6. The National High Technology Research and Development Program of China (863 program, 2006AA020403): Disease target prediction and analysis system, 2007.1-2010.12.

Publications

1. Dou X, Jiang L, Wang Y, Jin H, Liu Z, Zhang L. Discovery of new GSK-3β inhibitors through structure-based virtual screening. Bioorg Med Chem Lett. 2018 Jan 15;28(2):160-166.

2. Fan N, Zhang S, Sheng T, Zhao L, Liu Z, Liu J, Wang X. Docking Field-based QSAR and pharmacophore studies on the substituted pyrimidine derivatives targeting HIV-1 reverse transcriptase.ChemBiol Drug Des. 2017 Aug 17. doi: 10.1111/cbdd.13086.

3. Luo Q, Zhao L, Hu J, Jin H, Liu Z, Zhang L.The scoring bias in reverse docking and the score normalization strategy to improve success rate of target fishing.PLoS One. 2017 Feb 14;12(2):e0171433. doi: 10.1371.

4. Yang R, Zhang Y, Huang D, Luo X, Zhang L, Zhu X, Zhang X, Liu Z, Han JY, Xiong JW.Miconazole protects blood vessels from MMP9-dependent rupture and hemorrhage.Dis Model Mech. 2017 Mar 1;10(3):337-348.

5. Yu P, Xue X, Zhang J, Hu X, Wu Y, Jiang LH, Jin H, Luo J, Zhang L, Liu Z, Yang W. Identification of the ADPR binding pocket in the NUDT9 homology domain of TRPM2. J Gen Physiol. 2017 Feb;149(2):219-235

6. Shuang Zhang, Xiwen Xue, Liangren Zhang, Lihe Zhang and Zhenming Liu. Comparative Analysis of Pharmacophore Features and Quantitative Structure–Activity Relationships for CD38 Covalent and Non-covalent Inhibitors. CHEMICAL BIOLOGY & DRUG DESIGN. Article first published online : 14 JUL 2015, DOI: 10.1111/cbdd.12606

7. Lingxiao Zeng, Mengxin Guan, Hongwei Jin, Zhenming Liu and Liangren Zhang. Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example. CHEMICAL BIOLOGY & DRUG DESIGN. Article first published online : 14 JUL 2015, DOI: 10.1111/cbdd.12607

8. Fen Pei, Hongwei Jin, Xin Zhou, Jie Xia, Lidan Sun, Zhenming Liu and Liangren Zhang. Enrichment Assessment of Multiple Virtual Screening Strategies for Toll-Like Receptor 8 Agonists Based on a Maximal Unbiased Benchmarking Data Set. CHEMICAL BIOLOGY & DRUG DESIGN. Volume 86, Issue 5, November 2015, Pages: 1226–1241, Article first published online : 14 JUL 2015, DOI: 10.1111/cbdd.12590.

9. Yang, R.; Yan, S. Y.; Zhu, X. J.; Li, C. Y.; Liu, Z. M.; Xiong, J. W., Antimalarial drug artemisinin depletes erythrocytes by activating apoptotic pathways in zebrafish. Exp Hematol 2015, 43 (4), 331-341.

10. Xia, J.; Jin, H. W.; Liu, Z. M.; Zhang, L. R.; Wang, X. S., An Unbiased Method To Build Benchmarking Sets for Ligand-Based Virtual Screening and its Application To GPCRs. J. Chem Inf. Model. 2014, 54 (5), 1433-1450.

11. Sun, L. D.; Jin, H. W.; Zhao, X. Y.; Liu, Z. M.; Guan, Y. F.; Yang, Z. J.; Zhang, L. R.; Zhang, L. H., Unfolding and Conformational Variations of ThrombinBinding DNA Aptamers: Synthesis, Circular Dichroism and Molecular Dynamics Simulations. ChemMedChem 2014, 9 (5), 993-1001.

12. Wang, Z.; Li, S.; Sun, L.; Fan2, J.; Liu, Z., Comparative Analyses of Lipoprotein Lipase, Hepatic Lipase, and Endothelial Lipase, and Their Binding Properties with Known Inhibitors. Plos One 2013, 8 (8), e72146.

13. Sun, L. D.; Tian, F.; Feng, B. S.; Liu, Z. M.; Zhang, L. R.; Pei, J. F., Computational Identification of a New Binding Site in Influenza Virus Hemagglutinin for Membrane Fusion Inhibitors. Chem Biol Drug Des 2013, 82 (3), 267-274.

14. Liu, Z.; Graeff, R. M.; Jin, H.; Zhang, L.; Zhang, L., Studies on CD38 Inhibitors and Their Application to cADPR-Mediated Ca2+ Signaling. MESSENGER 2013, Vol. 2, 1-14.

15. Huang, W. L.; Zuo, T.; Luo, X.; Jin, H. W.; Liu, Z. M.; Yang, Z. J.; Yu, X. H.; Zhang, L. R.; Zhang, L. H., Indolizine Derivatives as HIV-1 VIFElonginC Interaction Inhibitors. Chem Biol Drug Des 2013, 81 (6), 730-741.

16. Huang, W. L.; Zuo, T.; Jin, H. W.; Liu, Z. M.; Yang, Z. J.; Yu, X. H.; Zhang, L. R.; Zhang, L. H., Design, synthesis and biological evaluation of indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors. Mol Divers 2013, 17 (2), 221-243.